Eisai's Alzheimer's drug Leqembi sales reach JPY 14.7bn in quarter

Eisai Co., Ltd. (TSE:4523) reported global sales revenue of JPY 14.7 billion for its anti-amyloid beta protofibril antibody "Lekenv" (generic name: lecanemab) in the fourth quarter of fiscal year 2024 (January 1, 2025 – March 31, 2025). Total revenue for fiscal year 2024 was JPY 44.3 billion. The figures are preliminary and unaudited. The announcement was made in conjunction with the first quarter 2025 earnings release by Biogen Inc. Further details regarding Lekenv's sales revenue, along with the company's consolidated financial results for the fiscal year ending March 2025, will be disclosed during Eisai's financial results announcement scheduled for May 15, 2025. Eisai leads development and regulatory submissions for lecanemab globally, with commercialization and promotion conducted jointly with Biogen under Eisai's final decision-making authority.